Provention Bio Stock Net Income
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Provention Bio's long-term financial health and intrinsic value.
Provention |
Provention Bio Company Net Income Analysis
Provention Bio's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Provention Bio Net Income | (113.56 M) |
Most of Provention Bio's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Provention Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Provention Bio reported net income of (113.56 Million). This is 133.28% lower than that of the Pharmaceuticals sector and 262.13% lower than that of the Health Care industry. The net income for all United States stocks is 119.89% higher than that of the company.
Provention Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Provention Bio's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Provention Bio could also be used in its relative valuation, which is a method of valuing Provention Bio by comparing valuation metrics of similar companies.Provention Bio is currently under evaluation in net income category among its peers.
Provention Fundamentals
| Return On Equity | -0.98 | |||
| Return On Asset | -0.43 | |||
| Operating Margin | (9.94) % | |||
| Current Valuation | 607.28 M | |||
| Shares Outstanding | 91.1 M | |||
| Shares Owned By Insiders | 4.61 % | |||
| Shares Owned By Institutions | 53.20 % | |||
| Number Of Shares Shorted | 5.37 M | |||
| Price To Book | 5.31 X | |||
| Price To Sales | 289.70 X | |||
| Revenue | 12.89 M | |||
| Gross Profit | (63.42 M) | |||
| EBITDA | (98.72 M) | |||
| Net Income | (113.56 M) | |||
| Cash And Equivalents | 84.52 M | |||
| Cash Per Share | 1.04 X | |||
| Total Debt | 23.47 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 3.59 X | |||
| Book Value Per Share | 1.39 X | |||
| Cash Flow From Operations | (75.41 M) | |||
| Short Ratio | 1.53 X | |||
| Earnings Per Share | (1.52) X | |||
| Target Price | 23.8 | |||
| Number Of Employees | 174 | |||
| Beta | 2.46 | |||
| Market Capitalization | 2.38 B | |||
| Total Asset | 236.86 M | |||
| Z Score | 60.6 | |||
| Net Asset | 236.86 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Provention Stock
If you are still planning to invest in Provention Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provention Bio's history and understand the potential risks before investing.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |